Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2012
03/28/2012EP2433496A1 Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
03/28/2012EP2433495A1 O-nitro compounds, pharmaceutical compositions thereof and uses thereof
03/28/2012EP2433133A2 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
03/28/2012EP2432882A2 TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
03/28/2012EP2432881A2 Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
03/28/2012EP2432880A1 Targeting micrornas for metabolic disorders
03/28/2012EP2432879A1 Use of inhibitors of zdhhc2 activity for modulation of adipogenesis
03/28/2012EP2432799A1 Cycloartanone derivatives with anticancer activity
03/28/2012EP2432798A2 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and use thereof for treating diseases
03/28/2012EP2432794A1 Trans-acting rna switches
03/28/2012EP2432792A1 N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl]-l-alanine 1-methylethyl ester and process for its production
03/28/2012EP2432788A1 Amorphous fosamprenavir calcium
03/28/2012EP2432784A1 Fused bicyclic pyrazole derivatives as kinase inhibitors
03/28/2012EP2432783A1 Modulators of 5-ht receptors and methods of use thereof
03/28/2012EP2432781A1 Salts of tiotropium with 10-camphorsulfonic acid
03/28/2012EP2432779A1 Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
03/28/2012EP2432776A1 Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
03/28/2012EP2432774A2 Compounds, compositions and methods for modulating uric acid levels
03/28/2012EP2432770A1 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
03/28/2012EP2432769A1 N-PHENYL-(PIPERAZINYL OR HOMOPIPERAZINYL)-BENZENESULFONAMIDE OR BENZENESULFONYL-PHENYL-(PIPERAZINE OR HOMOPIPERAZINE) COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR& xA;
03/28/2012EP2432768A1 Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
03/28/2012EP2432766A1 Anticancer compound and pharmaceutical composition containing the same
03/28/2012EP2432765A1 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
03/28/2012EP2432764A1 Substituted quinolines for use as vegf inhibitors
03/28/2012EP2432763A1 1,4 dihydropyridine derivatives and their uses
03/28/2012EP2432761A1 Treatment of muscle disease characterized by insulin resistance
03/28/2012EP2432556A1 Protease inhibitors
03/28/2012EP2432555A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
03/28/2012EP2432554A1 Heterocyclic antiviral compounds
03/28/2012EP2432553A2 Liquid dosage forms of isotretinoin
03/28/2012EP2432495A2 Elastin for soft tissue augmentation
03/28/2012EP2432492A2 Application and uses of prg4 and therapeutic modulation thereof
03/28/2012EP2432486A1 Compositions comprising compounds from palm oil mill effluents for use in the prevention and treatment of cardiovascular diseases
03/28/2012EP2432479A1 Extended acting oxygen generating composition for treating microbial infections
03/28/2012EP2432478A2 The improvement of gastrointestinal health, immunity and performance by dietary intervention
03/28/2012EP2432477A1 Methods and devices for improved efficiency of rna delivery to cells
03/28/2012EP2432476A1 Methods for treating or preventing ophthalmological diseases
03/28/2012EP2432475A1 A3 adenosine receptor agonists for the reduction of intraocular pressure
03/28/2012EP2432474A1 Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
03/28/2012EP2432473A1 Pyrazolopyrimidines and related heterocycles as kinase inhibitors
03/28/2012EP2432472A1 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
03/28/2012EP2432471A1 Novel therapeutic concepts for treating fibromyalgia
03/28/2012EP2432470A1 Treatment of heart failure with normal ejection fraction
03/28/2012EP2432469A1 Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl)pyridine and their therapeutical uses
03/28/2012EP2432468A2 Methods of modulating uric acid levels
03/28/2012EP2432467A1 Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
03/28/2012EP2432466A1 Schweinfurthins and uses thereof
03/28/2012EP2432465A1 Use of dynamin ring stabilizers
03/28/2012EP2432464A2 Nitrile derivatives and their pharmaceutical use and compositions
03/28/2012EP2432463A1 Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility
03/28/2012EP2432462A2 Endoxifen methods and compositions in the treatment of mammalian diseases
03/28/2012EP2432461A1 Opioid receptors stimulating compounds (thymoquinone, nigella sativa) and food allergy
03/28/2012EP2432460A1 Water dispersible glyceryl monooleate magnetic nanoparticle formulation
03/28/2012EP2432459A2 Oral compositions of celecoxib
03/28/2012EP2432456A1 Solid pharmaceutical compositions and processes for their production
03/28/2012EP2432455A2 Composition comprising oil drops
03/28/2012EP2432454A1 Compositions for continuous administration of dopa decarboxylase inhibitors
03/28/2012EP2432453A2 Topical retinoid solutions
03/28/2012EP2432452A1 Pharmaceutical oral telmisartan solution
03/28/2012EP2432451A2 Compositions for the treatment of metastatic cancer and methods of use thereof
03/28/2012EP2432444A1 Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof
03/28/2012EP2432328A1 Fat blends and uses thereof
03/28/2012EP2432320A1 Pharmaceutical co-crystals of quercetin
03/28/2012EP2432319A1 Method of treatment of obsessive compulsive disorder with ondansetron
03/28/2012EP2432318A1 Bimacrocyclic hcv ns3 protease inhibitors
03/28/2012EP2351732A8 Novel compound ramalin, and use thereof
03/28/2012EP2337580B1 Stabilized compositions for recombinantly produced factor viii
03/28/2012EP2326649B1 NOVEL PYRROLO[2,3-a]CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS
03/28/2012EP2313404B1 Quinuclidine carbonate derivatives and medicinal composition thereof
03/28/2012EP2297148B8 Novel derivatives of (bridged piperazinyl)-1-alcanone and use thereof as p75 inhibitors
03/28/2012EP2260048B1 Porous crystalline hybrid solid for adsorbing and releasing gas of biological interest
03/28/2012EP2252612B1 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
03/28/2012EP2250163B1 Hepatitis c virus inhibitors
03/28/2012EP2242738B1 Sgk1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas
03/28/2012EP2230943B1 Paediatric fibre mixture
03/28/2012EP2188276B1 Substituted hydantoins
03/28/2012EP2178878B1 Tetracyclic compounds for the treatment of hepatitis c
03/28/2012EP2155185B1 Detecting succinylacetone
03/28/2012EP2148862B1 Dihydroquinone and dihydronaphthridine inhibitors of jnk
03/28/2012EP2144640B1 Reduction of infection associated with medical device
03/28/2012EP2118087B1 Pi 3-kinase inhibitors and methods of their use
03/28/2012EP2099461B1 Lna nucleoside phosphoramidates
03/28/2012EP2046807B1 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
03/28/2012EP2043637B8 Methods and medicaments for administration of ibuprofen
03/28/2012EP1951690B1 Heterocyclic cetp inhibitors
03/28/2012EP1951233B1 Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf)
03/28/2012EP1934191B1 Biphenyl derivatives as modulators of voltage gated ion channels
03/28/2012EP1894919B1 Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
03/28/2012EP1807065B1 Methods and compositions for treating nephrogenic diabetes insipidus
03/28/2012EP1799685B1 Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
03/28/2012EP1799199B1 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
03/28/2012EP1765362B1 Compositions and methods for treatment of neovascular diseases
03/28/2012EP1682537B1 Modulators of cellular adhesion
03/28/2012EP1679058B1 Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases
03/28/2012EP1641783B1 Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
03/28/2012EP1579872B1 Body weight gain inhibitor
03/28/2012EP1543830B1 Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides
03/28/2012EP1527047B1 3-z- 1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-me thyl-amino)-anilino)-1-phenyl-methylene -6-methoxycarbonyl-2 -indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
03/28/2012EP1499580B1 Compounds that stimulate glucose utilization and methods of use
03/28/2012EP1472234B1 Quinazolinone derivatives and their use as cb agonists
1 ... 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 ... 7860